Inmune Bio INMB
NASDAQ INMB
$1.93 -0.02 (-1.03%)
At close: Oct 1, 2026 · 4:00 PM EDT

Inmune Bio (INMB) Liabilities and Shareholders Equity (2017 - 2026)

Updated

Inmune Bio's Liabilities and Shareholders Equity came in at $26.85 million for Q2 2026, down 28.8% from $37.68 million a year earlier but up 4.0% from the prior quarter.

Analysis

Inmune Bio (INMB) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends

At the end of FY2025, Inmune Bio's Liabilities and Shareholders Equity was $32.35 million, down 18.2% from FY2024.

  • Liabilities and Shareholders Equity has declined in each of the last four years, with a five-year compound annual growth rate of -4.5% (FY2020 to FY2025).
  • Going back by year, Liabilities and Shareholders Equity was $39.56 million in FY2024 (-30.6%), $57 million in FY2023 (-30.3%), $81.8 million in FY2022 (-18.2%) and $99.95 million in FY2021 (+145.8%).
  • The five-year range for quarterly Liabilities and Shareholders Equity is $25.82 million (Q1 2026) to $107.67 million (Q3 2021).
  • Year-over-year, Liabilities and Shareholders Equity has declined for 16 consecutive quarters, with an average decline of 26.2% over the last eight quarters.
  • The fastest year-over-year change in Liabilities and Shareholders Equity over five years came in Q3 2021 (growth of 151.5%), and the weakest in Q3 2025 (a decline of 36.8%).
  • Business Quant data shows INMB's Liabilities and Shareholders Equity at $25.82 million (Q1 2026), $32.35 million (Q4 2025) and $33.36 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 201.06 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 135.12 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 129.80 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 122.03 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 115.83 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 95.64 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 49.36 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 201.13 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 27.42 Bn
10 Inmune Bio 53.92 Mn -38.33 Mn - 26.85 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 26.85 Mn
Mar 31, 2026 25.82 Mn
Dec 31, 2025 32.35 Mn
Sep 30, 2025 33.36 Mn
Jun 30, 2025 37.68 Mn
Mar 31, 2025 37.80 Mn
Dec 31, 2024 39.56 Mn
Sep 30, 2024 52.78 Mn
Jun 30, 2024 52.45 Mn
Mar 31, 2024 46.83 Mn
Dec 31, 2023 57.00 Mn
Sep 30, 2023 62.70 Mn
Jun 30, 2023 69.72 Mn
Mar 31, 2023 73.98 Mn
Dec 31, 2022 81.80 Mn
Sep 30, 2022 83.80 Mn
Jun 30, 2022 87.81 Mn
Mar 31, 2022 94.35 Mn
Dec 31, 2021 99.95 Mn
Sep 30, 2021 107.67 Mn
API Access

Inmune Bio Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=INMB&period=max&api_key=YOUR_API_KEY